References
- Pallis AG, Papamichael D, Audisio R et al. EORTC Elderly Task Force experts’opinion for the treatment of colon cancer in older patients. Cancer Treat. Rev. 36 (1), 83–90 (2010).
- Jennens RR, Giles GG, Fox RM. Increasing underrepresentation of elderly patients with advanced colorectal or non-small-cell lung cancer in chemotherapy trials. Intern. Med. J. 36 (4), 216–220 (2006).
- Gross CP, McAvay GJ, Krumholz HM et al. The effect of age and chronic illness on life expectancy after a diagnosis of colorectal cancer: implications for screening. Ann. Intern. Med. 145 (9), 646–653 (2006).
- Sanoff HK, Bleiberg H, Goldberg RM. Managing older patients with colorectal cancer. J. Clin. Oncol. 25 (14), 1891–1897 (2007).
- Rosati G, Bilancia D. Role of chemotherapy and novel biological agents in the treatment of elderly patients with colorectal cancer. World J. Gastroenterol. 14 (12), 1812–1822 (2008).
- Koopman M, Antonini NF, Douma J et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 370 (9582), 135–142 (2007).
- Seymour MT, Maughan TS, Ledermann JA et al. Different strategies of sequential and combination chemotherapy for patients with poor-prognosis advanced colorectal cancer (MRC FOCUS): a randmised controlled trial. Lancet 370 (9582), 143–152 (2007).
- Falcone A, Ricci S, Brunetti I et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J. Clin. Oncol. 25 (13), 1670–1676 (2007).
- Figueras J, Ramos E, López-Ben S et al. Surgical treatment of liver metastases from colorectal carcinoma in elderly patients. When is it worthwhile? Clin. Transl. Oncol. 9 (6), 392–400 (2007).
- de Liguori Carino N, van Leeuwen BL, Ghaneh P et al. Liver resection for colorectal liver metastases in older patients. Crit Rev Oncol Hematol 67 (3), 273–278 (2008).
- Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J. Clin. Oncol. 22 (7), 1209–1214 (2004).
- Sargent DJ, Köhne CH, Sanoff HK et al. Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer. J. Clin. Oncol. 27 (12), 1948–1955 (2009).
- Rosati G, Cordio S, Bordonaro R et al. Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomized phase II study. Ann. Oncol. 21 (4), 781–786 (2010).
- Seymour MT, Thompson LC, Wasan HS et al. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet 377 (9779), 1749–1759 (2011).
- Di Bartolomeo M, Pietrantonio F, Martinetti A et al. Role of the antiangiogenic agent bevacizumab in the treatment of elderly patients with metastatic colorectal cancer. Drugs Aging 28 (2), 83–91 (2011).
- Cunningham D, Lang I, Lorusso V et al. Bevacizumab (bev) in combination with capecitabine (cape) for the first-line treatment of elderly patients with metastatic colorectal cancer (mCRC): results of a randomized international phase III trial (AVEX). J. Clin. Oncol. 30 ( Suppl. 34), abstract 337 (2012).
- Rosati G, Avallone A, Aprile G et al. XELOX and bevacizumab followed by single-agent bevacizumab as maintenance therapy as first-line treatment in elderly patients with advanced colorectal cancer: the boxe study. Cancer Chemother. Pharmacol. 71 (1), 257–264 (2013).
- Cassidy J, Saltz LB, Giantonio BJ et al. Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies. J. Cancer Res. Clin. Oncol. 136 (5), 737–743 (2010).
- Douillard JY, Siena S, Cassidy J et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J. Clin. Oncol. 28 (31), 4697–4705 (2010).
- Bouchahda M, Macarulla T, Spano JP et al. Cetuximab efficacy and safety in a retrospective cohort of elderly patients with heavily pretreated metastatic colorectal cancer. Crit. Rev. Oncol. Hematol. 67 (3), 255–262 (2008).